Additional gene-specific medicines that are currently being studied but have not yet been used in clinical practice include myosin activator medications (such as omecamtiv mecarbil) and the suppression of the mitogen-activated protein kinase signaling pathway in laminopathies [5]. Here, WNK2 is linked to laminopathy.